Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 24 of 38, showing 5 Applications out of 189 total, starting on record 116, ending on 120

# Protocol No Study Title Investigator(s) & Site(s)

116.

ECCT/24/06/02   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Jesse Gitaka
Site(s) in Kenya
1. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. KEMRI-Mtwapa Clinical Annex (Kilifi county)
4. University of Nairobi Clinical Research Centre (Nairobi City county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

117.

ECCT/24/08/03   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Mary Inziani Matilu
Site(s) in Kenya
1. KEMRI-Mtwapa Clinical Annex (Kilifi county)
2. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. University of Nairobi Clinical Research Centre (Nairobi City county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

118.

ECCT/24/09/02   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Teresa Kinyari
Site(s) in Kenya
1. University of Nairobi Clinical Research Centre (Nairobi City county)
2. KEMRI-Mtwapa Clinical Annex (Kilifi county)
3. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
4. Clinical Research Health Network (CREA-N) (Machakos county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

119.

ECCT/21/02/03   VAC078
    A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria.   
Principal Investigator(s)
1. Mainga Patience Mayeso Hamaluba
2. Jean Bosco Ouedraogo
3. Halidou Tinto
4. Alassane Dicko
5. Ally Olotu
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
View

120.

ECCT/24/05/03   SIBP-MMR-02
    A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age   
Principal Investigator(s)
1. Dr Walter Otieno
2. Dr. Diana Odhiambo
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. Victoria Biomedical Research Institute (Kisumu county)
 
View